Meiji Merger with Alvogen Bears Fruit, B2B Operations Boost Revenue to NT$19.945 Billion in First Seven Months, Up Nearly 70%

Meiji (1795-TW) announced today (10th) its July revenue of NT$2.492 billion, with cumulative revenue for the first seven months of the year reaching NT$19.945 billion, representing a year-on-year increase of nearly 70%. Meiji stated that the revenue performance was mainly supported by the gradually emerging benefits from the acquisition of Alvogen, coupled with strong momentum in its B2B business operations.

Meiji's July revenue amounted to NT$2.492 billion, down 26.68% month-on-month but up 3.96% year-on-year. Cumulative revenue for the first seven months reached NT$19.945 billion, up 67.97% compared to the same period last year.

The company noted that as of July, its U.S. operations benefited from the integration of Alvogen, generating revenue of NT$11.902 billion, a 133% year-on-year increase, accounting for 60% of total revenue. Asian operations remained stable with revenue of NT$6.354 billion, representing approximately 32% of total revenue.

Furthermore, Meiji highlighted that its B2B business achieved cumulative revenue of NT$1.688 billion in the first seven months, a 233% year-on-year increase, contributing about 9% to total revenue. The primary growth drivers were the successful launch of key products, including Nintedanib in the European and North American markets, and Enzalutamide in Brazil, Canada, and South Korea.